Logo image of XBIT

XBIOTECH INC (XBIT) Stock Fundamental Analysis

NASDAQ:XBIT - Nasdaq - CA98400H1029 - Common Stock - Currency: USD

3.18  -0.04 (-1.24%)

Fundamental Rating

3

XBIT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. While XBIT has a great health rating, there are worries on its profitability. XBIT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XBIT had negative earnings in the past year.
XBIT had a negative operating cash flow in the past year.
XBIT had negative earnings in each of the past 5 years.
XBIT had negative operating cash flow in 4 of the past 5 years.
XBIT Yearly Net Income VS EBIT VS OCF VS FCFXBIT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

XBIT has a Return On Assets of -21.67%. This is in the better half of the industry: XBIT outperforms 77.12% of its industry peers.
XBIT has a better Return On Equity (-22.56%) than 83.06% of its industry peers.
Industry RankSector Rank
ROA -21.67%
ROE -22.56%
ROIC N/A
ROA(3y)-14.6%
ROA(5y)-10.66%
ROE(3y)-15.43%
ROE(5y)-11.2%
ROIC(3y)N/A
ROIC(5y)N/A
XBIT Yearly ROA, ROE, ROICXBIT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

XBIT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XBIT Yearly Profit, Operating, Gross MarginsXBIT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

9

2. Health

2.1 Basic Checks

Compared to 1 year ago, XBIT has about the same amount of shares outstanding.
XBIT has less shares outstanding than it did 5 years ago.
The debt/assets ratio for XBIT is higher compared to a year ago.
XBIT Yearly Shares OutstandingXBIT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XBIT Yearly Total Debt VS Total AssetsXBIT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 7.54 indicates that XBIT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.54, XBIT belongs to the best of the industry, outperforming 82.52% of the companies in the same industry.
There is no outstanding debt for XBIT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.54
ROIC/WACCN/A
WACCN/A
XBIT Yearly LT Debt VS Equity VS FCFXBIT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 29.15 indicates that XBIT has no problem at all paying its short term obligations.
The Current ratio of XBIT (29.15) is better than 97.12% of its industry peers.
A Quick Ratio of 29.15 indicates that XBIT has no problem at all paying its short term obligations.
XBIT has a Quick ratio of 29.15. This is amongst the best in the industry. XBIT outperforms 97.12% of its industry peers.
Industry RankSector Rank
Current Ratio 29.15
Quick Ratio 29.15
XBIT Yearly Current Assets VS Current LiabilitesXBIT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for XBIT have decreased strongly by -28.07% in the last year.
EPS 1Y (TTM)-28.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XBIT Yearly Revenue VS EstimatesXBIT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 10M 20M 30M 40M
XBIT Yearly EPS VS EstimatesXBIT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2019 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XBIT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XBIT Price Earnings VS Forward Price EarningsXBIT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XBIT Per share dataXBIT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XBIT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XBIOTECH INC

NASDAQ:XBIT (7/3/2025, 8:18:15 PM)

3.18

-0.04 (-1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14
Earnings (Next)08-11 2025-08-11
Inst Owners14.92%
Inst Owner Change-8.96%
Ins Owners35.07%
Ins Owner Change0%
Market Cap96.96M
Analysts82.86
Price TargetN/A
Short Float %5.03%
Short Ratio9.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)-1.3
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0
BVpS5.73
TBVpS5.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.67%
ROE -22.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.6%
ROA(5y)-10.66%
ROE(3y)-15.43%
ROE(5y)-11.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.77%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 29.15
Quick Ratio 29.15
Altman-Z 7.54
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)39.36%
Cap/Depr(5y)83.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.18%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-111.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-110.08%
OCF growth 3YN/A
OCF growth 5YN/A